Abstract: The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3? end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.

Abstract: The disclosure relates to compositions comprising a HBV RNAi agent. In some embodiments, the HBV RNAi agent comprises a sense and an anti-sense strand, each strand being an 18-mer and the strands together forming a blunt-ended duplex, wherein the 3? end of at least one strand terminates in a phosphate or modified internucleoside linker and further comprises, in 5? to 3? order: a spacer; a second phosphate or modified internucleoside linker; and a 3? end cap. In some embodiments, the 3? end of both the sense and anti-sense strand further comprise, in 5? to 3? order: a spacer; a second phosphate or modified internucleoside linker; and a 3? end cap. The two strands can have the same or different spacers, phosphates or modified internucleoside linkers, and/or 3? end caps. The strands can be ribonucleotides, or, optionally, one or more nucleotide can be modified or substituted. Optionally, at least one nucleotide comprises a modified internucleoside linker.

Abstract: The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3? end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.

Abstract: The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3? end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.

Abstract: A service provider may collect information about items offered by merchants and prices for the items. The service provider may use the collected information to determine whether to recruit the merchant to join an electronic marketplace to offer one or more items for consumption. The service provider may receive the information from customer submissions, from monitoring payment processing data accessible to the service provider, or both. The service provider may collect various pieces of information about the seller and/or items offered by the seller. The collected information may include contact information of the seller, location information of the seller, a price of the item, an inventory or availability of the item, special options, and so forth, which may differentiate the seller and/or the item from other available sellers and items accessible through the electronic marketplace.

Abstract: The disclosure relates to compositions comprising a RNAi agent having a novel format including a spacer subunit. The disclosure relates to compositions comprising a RNAi agent having a novel format: an 18-mer format with at least one internal spacer. These RNAi agents comprise a first and a second 18-mer strand, wherein the first strand is 18 ribonucleotides or 18 total ribonucleotides and spacer subunit(s), and the second strand is 18 total ribonucleotides and spacer subunit(s), wherein: each spacer subunit consists of: (a) a phosphate or modified internucleoside linker and (b) a spacer; a spacer subunit can be at any position in the strand; the two strands form a duplex with at least one blunt end; and the 3 end of one or both strands terminates in a phosphate or modified internucleoside linker and further comprises, in 5 to 3 order: a second spacer; a second phosphate or modified internucleoside linker, and a 3 end cap.

Abstract: The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3? end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.

Abstract: The disclosure relates to compositions comprising a RNAi agent having a novel format including a spacer subunit. The disclosure relates to compositions comprising a RNAi agent having a novel format: an 18-mer format with at least one internal spacer. These RNAi agents comprise a first and a second 18-mer strand, wherein the first strand is 18 ribonucleotides or 18 total ribonucleotides and spacer subunit(s), and the second strand is 18 total ribonucleotides and spacer subunit(s), wherein: each spacer subunit consists of: (a) a phosphate or modified internucleoside linker and (b) a spacer; a spacer subunit can be at any position in the strand; the two strands form a duplex with at least one blunt end; and the 3 end of one or both strands terminates in a phosphate or modified internucleoside linker and further comprises, in 5 to 3 order: a second spacer; a second phosphate or modified internucleoside linker, and a 3 end cap.

Abstract: The disclosure relates to compositions comprising a HBV RNAi agent. In some embodiments, the HBV RNAi agent comprises a sense and an anti-sense strand, each strand being an 18-mer and the strands together forming a blunt-ended duplex, wherein the 3? end of at least one strand terminates in a phosphate or modified internucleoside linker and further comprises, in 5? to 3? order: a spacer; a second phosphate or modified internucleoside linker; and a 3? end cap. In some embodiments, the 3? end of both the sense and anti-sense strand further comprise, in 5? to 3? order: a spacer; a second phosphate or modified internucleoside linker; and a 3? end cap. The two strands can have the same or different spacers, phosphates or modified internucleoside linkers, and/or 3? end caps. The strands can be ribonucleotides, or, optionally, one or more nucleotide can be modified or substituted. Optionally, at least one nucleotide comprises a modified internucleoside linker.